79 related articles for article (PubMed ID: 20142048)
1. [Prostate cancer: medicoeconomic aspects].
Kanso C; Etner J; Debré B; Zerbib M
Prog Urol; 2010 Feb; 20(2):85-90. PubMed ID: 20142048
[TBL] [Abstract][Full Text] [Related]
2. Economic and organizational aspects in the management of prostate cancer.
Cellini N; Luzi S; Morganti AG; Mattiucci GC; Smaniotto D; Racioppi M
Rays; 1999; 24(3):460-71. PubMed ID: 10605307
[TBL] [Abstract][Full Text] [Related]
3. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
6. [Prostatic cancer: an expensive dilemma].
Borre M; Nerstrøm B; Overgaard J
Ugeskr Laeger; 1997 Apr; 159(17):2534-7. PubMed ID: 9182381
[TBL] [Abstract][Full Text] [Related]
7. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Littrup PJ
Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
[TBL] [Abstract][Full Text] [Related]
8. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
[TBL] [Abstract][Full Text] [Related]
9. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.
Mouraviev V; Nosnik I; Sun L; Robertson CN; Walther P; Albala D; Moul JW; Polascik TJ
Urology; 2007 Feb; 69(2):311-4. PubMed ID: 17320670
[TBL] [Abstract][Full Text] [Related]
10. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
11. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
Bolenz C; Gupta A; Hotze T; Ho R; Cadeddu JA; Roehrborn CG; Lotan Y
Eur Urol; 2010 Mar; 57(3):453-8. PubMed ID: 19931979
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of prostate cancer, California, 1998.
Max W; Rice DP; Sung HY; Michel M; Breuer W; Zhang X
Cancer; 2002 Jun; 94(11):2906-13. PubMed ID: 12115378
[TBL] [Abstract][Full Text] [Related]
14. [Economic aspects of conformal radiotherapy].
Martin P; Dubray B
Cancer Radiother; 1999; 3(5):437-40. PubMed ID: 10572513
[TBL] [Abstract][Full Text] [Related]
15. Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project.
Littrup PJ; Goodman AC
In Vivo; 1994; 8(3):423-7. PubMed ID: 7803728
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
[TBL] [Abstract][Full Text] [Related]
17. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
18. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma of the prostate: an expensive way to die.
Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
[TBL] [Abstract][Full Text] [Related]
20. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
Rohde V; Wellmann A; Fogt F; Weidner W; Katalinic A
Oncol Rep; 2002; 9(6):1185-8. PubMed ID: 12375016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
